MaxCyte, Inc.
MXCT
Rank in Stocks
#18411
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.30
Last synced: 2026-11-09
Market Cap
$134.17M
Change (1 day)
3.17%
Change (1 year)
-16.13%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MaxCyte, Inc. (MXCT)
Category
Healthcare
EPS for MaxCyte, Inc. (MXCT)
EPS as of June 2026 TTM: $-0.33
According to MaxCyte, Inc.'s latest financial reports, its current EPS (TTM) is $-0.33. At the end of 2025 the company had an EPS of $-0.42, a decrease compared to its 2024 EPS of $-0.39.
EPS history for MaxCyte, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.33 | -21.43% |
| 2025 | $-0.42 | 7.69% |
| 2024 | $-0.39 | 5.41% |
| 2023 | $-0.37 | 94.74% |
| 2022 | $-0.19 | -13.64% |
| 2021 | $-0.22 | 22.22% |
| 2020 | $-0.18 | -25.00% |
| 2019 | $-0.24 | 41.18% |
| 2018 | $-0.17 | -15.00% |
| 2017 | $-0.20 | 100.40% |
| 2016 | $-0.10 | 199.70% |
| 2015 | $-0.03 | -97.91% |
| 2014 | $-1.59 | 7,127.27% |
| 2013 | $-0.02 | -51.86% |
| 2012 | $-0.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -4,845.45% |
US
|
|
| $-7.07 | 2,042.42% |
US
|
|
| $-5.29 | 1,503.03% |
AU
|
|
| $12.88 | -4,003.06% |
BE
|
|
| $21.56 | -6,633.33% |
NL
|
Questions about MaxCyte, Inc.'s earnings per share (EPS)
What is MaxCyte, Inc.'s earnings per share (EPS)?
MaxCyte, Inc.'s earnings per share (EPS) over the last twelve months is $-0.33, as of Jun 2026.
What was MaxCyte, Inc.'s earnings per share (EPS) in 2025?
In 2025, MaxCyte, Inc.'s earnings per share (EPS) was $-0.42, compared with $-0.39 in 2024.
How has MaxCyte, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.18) and lowest in 2025 ($-0.42).
How does MaxCyte, Inc.'s earnings per share (EPS) compare with similar companies?
MaxCyte, Inc.'s earnings per share (EPS) ($-0.33) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.